Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 20, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Prostate specific antigen best practice statement: 2009 update.

Kirsten L Greene1, Peter C Albertsen, Richard J Babaian

  • 1American Urological Association Education and Research, Inc, Linthicum, Maryland 21090, USA.

The Journal of Urology
|September 29, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202.

Advances in radiation oncology·2026
Same author

Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

The Red Journal at Fifty.

International journal of radiation oncology, biology, physics·2025
Same author

Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial.

European urology oncology·2025
Same author

Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.

Communications medicine·2024
Same journal

On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

The Journal of urology·2026
Same journal

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

The Journal of urology·2026
Same journal

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The Journal of urology·2026
Same journal

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

The Journal of urology·2026
Same journal

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

The Journal of urology·2026
Same journal

Endourology and Nephrolithiasis.

The Journal of urology·2026
See all related articles

Prostate cancer screening using prostate-specific antigen (PSA) testing has evolved. Men should discuss the risks and benefits of early detection, including overdetection and overtreatment, with their doctor.

Area of Science:

  • Urology
  • Oncology
  • Preventive Medicine

Background:

  • Prostate cancer remains a significant health concern for men.
  • Early detection through prostate-specific antigen (PSA) testing is a key strategy.
  • Understanding the risks and benefits of PSA testing is crucial for informed decision-making.

Purpose of the Study:

  • To provide current information on PSA testing for men at risk of prostate cancer.
  • To outline the risks and benefits associated with early prostate cancer detection.
  • To summarize the 2009 American Urological Association PSA Best Practice Policy.

Main Methods:

  • Review of current professional literature.
  • Incorporation of clinical experience.
  • Expert opinions from a multispecialty panel.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Related Experiment Videos

Last Updated: Jun 20, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Main Results:

  • Baseline PSA testing age lowered to 40 years.
  • No single PSA threshold value recommended for prostate biopsy.
  • Biopsy decisions should consider multiple factors beyond PSA and digital rectal exam (DRE).

Conclusions:

  • Prostate cancer screening may lead to overdetection and overtreatment.
  • Men should be informed about screening risks and benefits before biopsy.
  • Active surveillance is an option for certain men diagnosed with prostate cancer.